CytoSorbents Prepares for Growth as DrugSorb Review Nears
Princeton, NJ – December 2025 – CytoSorbents, a pioneer in hemoadsorption and blood-purification technologies, is drawing renewed attention as...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development EMA FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Princeton, NJ – December 2025 – CytoSorbents, a pioneer in hemoadsorption and blood-purification technologies, is drawing renewed attention as...
Dublin, Ireland – December 9, 2025 – ProVerum Limited announced that the U.S. Food and Drug Administration has granted...
